SCHEMBL6490973

SCHEMBL6490973

CCOC(=O)CCCOc1cc(C)c2nc(CC)n(Cc3ccc(Cl)cc3Cl)c2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
NPY1R P25929 2/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MCL1 Q07820 3/20 0.39
PLA2G2A P14555 3/20 0.39
ALOX5AP P20292 1/20 0.38
CYSLTR2 Q9NS75 2/20 0.37
CYSLTR1 Q9Y271 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
HPGD P15428 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
BRD4 O60885 1/20 0.37
MAPT P10636 2/20 0.36
PABPC1 P11940 1/20 0.36
FAAH O00519 2/20 0.36
BCL2L1 Q07817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489668 0.91 MCL1 (0.44) SMN1; SMN2LMNAMCL1PLA2G2AALOX5AP
SCHEMBL6502915 0.91 SMN1; SMN2 (0.44) SMN1; SMN2LMNANPY1RMEN1KMT2A
SCHEMBL6490102 0.90 LMNA (0.43) SMN1; SMN2LMNANPY1RMEN1KMT2A
SCHEMBL6499497 0.89 SMN1; SMN2 (0.42) SMN1; SMN2LMNANPY1RMEN1KMT2A
SCHEMBL6502885 0.88 SMN1; SMN2 (0.42) SMN1; SMN2LMNANPY1RMEN1KMT2A
SCHEMBL6488064 0.87 SMN1; SMN2 (0.41) SMN1; SMN2LMNANPY1RMEN1KMT2A
SCHEMBL6499832 0.84 PLA2G2A (0.42) LMNAMCL1PLA2G2ACYSLTR2CYSLTR1
SCHEMBL6488906 0.84 MEN1 (0.40) SMN1; SMN2LMNANPY1RMEN1KMT2A
SCHEMBL6488241 0.83 MCL1 (0.43) KMT2AMCL1PLA2G2ACYSLTR2CYSLTR1
SCHEMBL6491512 0.82 MCL1 (0.41) LMNAMEN1KMT2AMCL1PLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD SMN1; SMN2 1128/4885LMNA 3711/4885NPY1R 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.